A-Alpha Bio

A-Alpha Bio

Biotechnology Research

Seattle, Washington 7,619 followers

The protein-protein interaction company

About us

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/

Website
https://www.aalphabio.com/
Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Seattle, Washington
Type
Privately Held
Founded
2017
Specialties
Drug discovery, Protein Engineering, Synthetic Biology, Immunocytokines, Molecular Glues, Oncology, and Protein-protein interactions

Locations

Employees at A-Alpha Bio

Updates

Similar pages

Browse jobs

Funding

A-Alpha Bio 9 total rounds

Last Round

Grant

US$ 14.5M

See more info on crunchbase